Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dimitris V Rados"'
Autor:
Rudi Roman, Karine Margarites Lima, Maria Angela Fontoura Moreira, Roberto Nunes Umpierre, Lisiane Hauser, Dimitris V Rados, Alvaro Vigo, Marcelo Rodrigues Gonçalves, Sotero Serrate Mengue, Erno Harzheim
Publikováno v:
Revista Brasileira de Medicina de Família e Comunidade, Vol 14, Iss 41 (2019)
Objective: The mere dissemination of standard care recommendations has been insufficient to improve clinical results in patients with asthma. The objective of the present study was to evaluate the clinical effectiveness of a multifaceted asthma dista
Externí odkaz:
https://doaj.org/article/a5f1dd386d324c77bd69f5a114d4035a
Autor:
Natália Diel Boufleuer, Dimitris V. Rados, Tatiana Zambonato, Clara K. Maraschin, Beatriz D. Schaan
Publikováno v:
Case Reports in Endocrinology, Vol 2024 (2024)
Introduction. The triad of hypercalcemia, metabolic alkalosis, and acute kidney injury associated with ingesting high doses of calcium and absorbable bases characterizes the calcium-alkali syndrome. Clinical Case. We report the case of a patient with
Externí odkaz:
https://doaj.org/article/e1306f1335e248e2b302e3329e48574d
Autor:
Lana C. Pinto, Dimitris V. Rados, Luciana R. Remonti, Marina V. Viana, Cristiane B. Leitão, Jorge L. Gross
Publikováno v:
Archives of Endocrinology and Metabolism, Volume: 66, Issue: 1, Pages: 68-76, Published: 16 MAR 2022
Archives of Endocrinology and Metabolism v.66 n.1 2022
Arquivos de Endocrinologia e Metabolismo
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron:SBEM
Archives of Endocrinology and Metabolism v.66 n.1 2022
Arquivos de Endocrinologia e Metabolismo
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron:SBEM
The lowest dosage of empagliflozin (10 mg) showed similar benefits on glycated hemoglobin (HbA1c) level, body weight, blood pressure, and total and cardiovascular mortality in comparison with the highest available dose (25 mg) in the EMPAREG trial. T
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
Abstract The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both
Externí odkaz:
https://doaj.org/article/81b767a656f546529e3bc567694357bf